KYE Pharmaceuticals
KYE Pharmaceuticals is a Canadian specialty pharmaceutical company founded in 2019 that licenses and commercializes innovative prescription medicines from global partners for exclusive distribution across Canada, spanning ADHD, rare diseases, hematology, cardiology, and pediatric therapeutic areas.
- Company typePrivate
- Founded2019
- HeadquartersMississauga, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What KYE Pharmaceuticals does
KYE Pharmaceuticals is a Canadian specialty pharmaceutical company founded in 2019 by Doug Reynolds and headquartered in Mississauga, Ontario. The company identifies areas of significant clinical unmet need and licenses or acquires innovative prescription medicines from global pharmaceutical partners for exclusive commercialization in the Canadian market, spanning therapeutic areas that include ADHD, cardiology, pediatrics, neuroscience, rare diseases, hematology, and neuromuscular disorders. Its marketed portfolio includes Dyanavel XR (amphetamine extended-release tablets and oral suspension), Quillivant ER (methylphenidate extended-release chewable tablets and oral suspension), ACCRUFeR (ferric maltol), AGAMREE (vamorolone), FIRDAPSE (amifampridine phosphate), CORZYNA (ranolazine extended-release), KYE-ESCITALOPRAM, and SLENYTO (extended-release melatonin). Several products hold first-in-class Health Canada approvals, and the ADHD portfolio leverages Tris Pharma's proprietary LiquiXR extended-release drug delivery technology through a multi-product licensing arrangement.
The company's business model is licensing-driven rather than R&D-driven: KYE does not develop proprietary molecules but secures exclusive Canadian rights from international partners including Tris Pharma, Shield Therapeutics, Catalyst Pharmaceuticals, Neurim Pharmaceuticals, and Hyloris Pharmaceuticals, then handles regulatory registration, pricing, reimbursement, marketing, and distribution. Revenue is generated through pharmaceutical product sales via Canadian distribution channels, including retail pharmacies, wholesalers, and direct engagement with healthcare professionals (pediatricians, psychiatrists, GPs). The company maintains dedicated commercial leads for ADHD and General Medicines, patient support programs across all provinces except Quebec, and a pipeline of additional candidates spanning ADHD, neuromuscular, rare disease, gastrointestinal, pediatrics, and women's health with anticipated launches through 2027.
Operationally, KYE is a lean organization with 11-50 employees, commercial-stage status, PIPEDA-compliant privacy practices, and recognition on the Globe & Mail 2025 Canada's Top Growing Companies list. The company is privately held with no disclosed parent entity; leadership includes President John McKendry (formerly of Pfizer), founder/Executive Chairman Doug Reynolds, and a board drawn from Tris Pharma, CPOINT Capital, and Aspire Pharma.
KYE Pharmaceuticals firmographics
Firmographics- Name
- KYE Pharmaceuticals
- Legal name
- KYE Pharmaceuticals Inc.
- Website
- https://kyepharma.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- KYE Pharmaceuticals is a Canadian specialty pharmaceutical company founded in 2019 that licenses and commercializes innovative prescription medicines from global partners for exclusive distribution across Canada, spanning ADHD, rare diseases, hematology, cardiology, and pediatric therapeutic areas.
- Ownership category
- akta.pro rank
KYE Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where KYE Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
KYE Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Pharmaceutical Product Sales: KYE generates revenue through commercializing licensed pharmaceutical products in Canada. The company licenses innovative medicines from global pharmaceutical and biotechnology companies and commercializes them through Canadian distribution channels including pharmacies and wholesalers.
- Licensing and Royalty Arrangements: Under licensing agreements, KYE receives exclusive Canadian rights to commercialize products. Partners such as Shield Therapeutics, Catalyst Pharmaceuticals, Neurim Pharmaceuticals, Tris Pharma, and Hyloris provide product supply while KYE handles regulatory, marketing, and commercialization activities in Canada.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
KYE Pharmaceuticals product offering
Product offeringCore offering
KYE Pharmaceuticals is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription medicines for the Canadian market. The company acquires or licenses innovative therapies from global pharmaceutical partners, handles Canadian regulatory affairs, pricing, reimbursement, and commercialization, and distributes through pharmacies and wholesalers across Canada. Its marketed portfolio spans ADHD, stable angina, depression, Lambert-Eaton Myasthenic Syndrome, iron deficiency anemia, Duchenne Muscular Dystrophy, and pediatric insomnia.
Product overview
KYE Pharmaceuticals is a Canadian specialty pharmaceutical company focused on licensing and commercializing innovative prescription medicines for the Canadian market. The company operates a diversified portfolio of marketed products and a robust pipeline spanning multiple therapeutic areas including cardiology, psychiatry, neurology, rare diseases, neuromuscular disorders, hematology, and pediatrics. The marketed product portfolio includes: CORZYNA (ranolazine extended-release tablets) for stable angina; KYE-ESCITALOPRAM (escitalopram oxalate) for depression; FIRDAPSE (amifampridine phosphate) for Lambert-Eaton Myasthenic Syndrome; QUILLIVANT ER (methylphenidate extended-release in chewable tablets and oral suspension formulations) for ADHD in children; ACCRUFeR (ferric maltol) for iron deficiency anemia; AGAMREE (vamorolone) for Duchenne Muscular Dystrophy; DYANAVEL XR (amphetamine extended-release in tablets and oral suspension) for ADHD; and SLENYTO (extended-release melatonin) for insomnia in children with ASD/SMS. The company also maintains a pipeline of products in development across ADHD, neuromuscular, rare disease, gastrointestinal, pediatrics, and women's health therapeutic areas with anticipated launches spanning 2026-2028.
Differentiator
Problem solved
Functional benefit
Products and services
- CORZYNA (ranolazine extended-release tablets) Ranolazine extended-release tablets indicated as add-on therapy for symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies.
- KYE-ESCITALOPRAM (escitalopram oxalate tablets)
Quantifiable outcome
- First and only extended-release amphetamine in Canada that can be chewed or swallowed whole
- +3 more outcomes
Companies that use KYE Pharmaceuticals
Customer profileNamed customers3 records
Segments4 records
KYE Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
KYE Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Neurim PharmaceuticalscoreLicensing and distribution agreement for SLENYTO (extended-release melatonin), the first prescription extended-release melatonin for treating insomnia in children with ASD/SMS. KYE handles regulatory, commercialization, and distribution activities in Canada. Health Canada approved SLENYTO on September 8, 2025.
- European Specialty Pharmaceutical CompanyminorExclusive license, supply, and commercialization agreement for a novel oral proton pump inhibitor (PPI) treatment for GERD in infants, children, and adults. KYE has exclusive Canadian rights and will handle all regulatory, marketing, and commercialization activities. Health Canada approval anticipated in 2026.
- Catalyst PharmaceuticalscoreExclusive license, supply, and commercialization agreement for AGAMREE (vamorolone) for Duchenne Muscular Dystrophy treatment in Canada. KYE funds all regulatory, marketing, and commercialization activities while Catalyst supplies the product. Health Canada approved AGAMREE in October 2025. KYE also commercializes Catalyst's FIRDAPSE for Lambert-Eaton Myasthenic Syndrome.
- Hyloris PharmaceuticalsminorPartnership for development and commercialization of Atomoxetine Oral Solution in Canada for ADHD treatment. KYE holds exclusive Canadian rights and is responsible for registration and commercialization. Atomoxetine is a non-stimulant medication providing an alternative formulation for patients with swallowing difficulties.
- Tris PharmacoreMulti-product partnership with Tris Pharma for ADHD medications. Tris developed proprietary LiquiXR extended-release technology used in Dyanavel XR (amphetamine) and Quillivant ER (methylphenidate) products. KYE holds exclusive Canadian rights while Tris manufactures and exports from the US. This partnership forms the core of KYE's ADHD portfolio.
- Shield TherapeuticscoreLicensing agreement for ACCRUFeR (ferric maltol) for iron deficiency anemia treatment in Canada. Shield supplies the product while KYE handles all regulatory, marketing, and commercialization activities. ACCRUFeR received Health Canada approval in August 2024 and became available in March 2025.
- Defeat Duchenne CanadaminorPatient advocacy organization that invested over $20 million over 30 years into DMD research. Funded clinical trials including open-label studies for AGAMREE with boys from five trial sites across Canada, supporting Health Canada approval.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
KYE Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Pharmascience: Major privately held Canadian pharmaceutical manufacturer and distributor with branded specialty and generic portfolios. Comparable as a Canadian pharma operator but at significantly larger scale.
- Novartis Pharmaceuticals Canada: Canadian arm of a global innovative pharmaceutical company with broad specialty and rare-disease portfolios. Relevant as a deep-pocketed commercial incumbent in Canadian specialty categories where KYE also operates.
- Bausch Health Companies: Large Canadian-headquartered specialty pharma with broad portfolios across neurology, gastroenterology, and dermatology. Comparable product categories but operates at materially greater scale and broader geographic reach.
- Apotex: Largest Canadian-owned pharmaceutical company, primarily generics with branded specialty exposure. Overlaps with KYE on Canadian pharmaceutical commercialization, but at much larger scale and broader portfolio.
Direct peers
- Verity Pharmaceuticals: Canadian specialty pharma commercializing licensed women's-health, fertility, and rare-disease prescription products. Comparable in license-in commercial model and Canadian specialty focus, with overlap in women's health and rare disease.
- Knight Therapeutics: Montreal-based specialty pharmaceutical company that in-licenses and commercializes innovative products in Canada and select emerging markets. Closely comparable business model, regulatory posture, and go-to-market focus to KYE.
- Cipher Pharmaceuticals: Canadian specialty pharma focused on acquiring, licensing, and commercializing prescription products across dermatology, neurology, and hospital specialty. Highly comparable as a small Canadian commercial-stage licensing business.
- Duchesnay: Canadian specialty pharmaceutical company focused on women's health and rare diseases, commercializing licensed products across Canada. Highly comparable therapeutic-area focus and Canadian specialty model.
- Hyloris Pharmaceuticals: Partner of KYE for atomoxetine oral solution; Belgium-based specialty pharma developing and licensing differentiated pharmaceutical products across Europe, the US, and Canada. Comparable licensing-and-commercialization model and product focus.
- Mint Pharmaceuticals: Canadian pharmaceutical company partnering with KYE (listed as a KYE partnering page partner). Comparable Canadian commercial pharma footprint and licensing-oriented approach.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
KYE Pharmaceuticals social profiles
Digital presenceKYE Pharmaceuticals compliance and trust
Trust signalCompliance1 record
KYE Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
KYE Pharmaceuticals leadership team
Management profileNumber of profiles
KYE Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KYE Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KYE Pharmaceuticals
What does KYE Pharmaceuticals do?
KYE Pharmaceuticals is a Canadian specialty pharmaceutical company that licenses and commercializes innovative prescription medicines for the Canadian market. The company acquires or licenses innovative therapies from global pharmaceutical partners, handles Canadian regulatory affairs, pricing, reimbursement, and commercialization, and distributes through pharmacies and wholesalers across Canada. Its marketed portfolio spans ADHD, stable angina, depression, Lambert-Eaton Myasthenic Syndrome, iron deficiency anemia, Duchenne Muscular Dystrophy, and pediatric insomnia.
Is KYE Pharmaceuticals a public or private company?
KYE Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was KYE Pharmaceuticals founded?
KYE Pharmaceuticals was founded in 2019. It employs 11 to 50 people.
Where is KYE Pharmaceuticals based?
KYE Pharmaceuticals is headquartered in Mississauga, Canada, in the North America region.
How does KYE Pharmaceuticals make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Royalty Arrangements.
Who are KYE Pharmaceuticals's main competitors?
Broad incumbents on record are Pharmascience, Novartis Pharmaceuticals Canada, Bausch Health Companies and Apotex. Direct peers are Verity Pharmaceuticals, Knight Therapeutics, Cipher Pharmaceuticals, Duchesnay, Hyloris Pharmaceuticals and Mint Pharmaceuticals.
Does KYE Pharmaceuticals have an API?
No public API is recorded for KYE Pharmaceuticals.
What industry is KYE Pharmaceuticals in?
KYE Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 5122.